Dr. Greg Glenn is a seasoned biotech leader with a proven track record in vaccine development and executive management. Following a research fellowship at the Walter Reed Army Institute of Research, Dr. Glenn founded IOMAI Corporation, leading it from startup to acquisition. As President of R&D at Novavax Inc., he played a pivotal role in developing and licensing Nuvaxovid and securing key funding, including Operation Warp Speed. Dr. Glenn also contributed to the WHO-endorsed R21/Matrix Malaria Vaccine. In 2024, he became CEO of Pinion Immunotherapeutics, driving innovation in immunotherapy.

Dr. Renhuan Xu is a distinguished expert in immunology with over 20 years of industry experience spanning cancer immunotherapy, infectious disease prevention, and vaccine development. He earned his Ph.D. in Immunology from Shanghai Jiaotong University, School of Medicine, and completed postdoctoral training at Fox Chase Cancer Center in Philadelphia, PA.

Dr. Xu is a co-founder of Pinion, where he has applied his extensive expertise to advance innovative solutions in immunotherapy and vaccine science.

Dr. Reggie Jakacki is a highly regarded expert in pediatric oncology and drug development with extensive experience spanning academia, clinical practice, and the biotech industry. She completed a fellowship in Pediatric Hematology/Oncology at the Children's Hospital of Philadelphia and served as a Professor of Pediatric Hematology/Oncology at the University of Pittsburgh.

At the University of Pittsburgh, Dr. Jakacki directed both the Pediatric Neuro-Oncology Program and the Drug Development Program, advancing groundbreaking therapies for pediatric cancer. She has also held senior roles in oncology at AstraZeneca and Johnson & Johnson and has served as a consultant for multiple biotech companies.

Dr. Jianzhu Chen is a co-founder of Pinion and a renowned immunologist with over 30 years of experience in academia and biotechnology. He is a Professor of Immunology at the Massachusetts Institute of Technology (MIT) and a member of the prestigious Koch Institute for Integrative Cancer Research.

Dr. Chen earned his Ph.D. at Stanford University and completed postdoctoral training at Harvard University.